Navigation Links
Why do certain diseases go into remission during pregnancy?
Date:6/16/2010

ANN ARBOR, MI -- During pregnancy, many women experience remission of autoimmune diseases like multiple sclerosis and uveitis. Now, scientists have described a biological mechanism responsible for changes in the immune system that helps to explain the remission.

The expression of an enzyme known as pyruvate kinase is reduced in immune cells in pregnant women compared to non-pregnant women, according to Howard R. Petty, Ph.D., biophysicist at the University of Michigan Kellogg Eye Center and Roberto Romero, M.D., of the National Institutes for Health. The study, which appears online ahead of print in the August issue of the American Journal of Reproductive Immunology, also reports that expression of the enzyme is lower in pregnant women compared to those with pre-eclampsia, a condition with inflammatory components.

The study is significant because the newly discovered mechanism points to a pathway that could be targeted for treatment. "It may be possible to design drugs that mildly suppress pyruvate kinase activity as a means of replicating the immune status of normal pregnancy," says Petty. In addition to pre-eclampsia, he believes that rheumatoid arthritis, type 1 diabetes, and uveitis may eventually yield to similarly designed drugs.

In his search to explain the phenomenon, Petty knew to look for a metabolic pathway or mechanism with two characteristics. It had to "dial down" the intensity of the normal immune response, an action needed so that a pregnant woman does not reject the fetus, which has proteins from the father that are "foreign" to the mother. At the same time, such a mechanism must support cell growth needed by the developing fetus.

The activity of the enzyme pyruvate kinaseand and its product, pyruvatefills both roles: promoting cell growth while modifying the immune response. Because pyruvate kinase activity is depressed during pregnancy, cell metabolism supports an increased production of lipids, carbohydrates, amino acids, and other substances that support cell growth.

Petty explains that our normal robust immune response depends upon pyruvate to promote calcium signaling, which, in turn, stimulates the production of messenger molecules called cytokines. When pyruvate is decreased during pregnancy, calcium signaling is also reduced, and the immune response is different than that in non-pregnant individuals.

Says Petty, "Modification of signaling along this pathway allows the pregnant woman to maintain an immune response, but at a level that will not harm the fetus."

The study included 21 women in their third trimester of a normal pregnancy, 25 women with pre-eclampsia, and a control group of non-pregnant women. Petty and colleagues used a variety of methods to confirm their findings, including fluorescence microscopy and flow cytometry, which are used to study cell signaling.

The higher levels of the enzyme seen in women with pre-eclampsia bolster the study's findings, says Petty.

"Pre-eclampsia has features of inflammatory disease. If you don't reduce these pyruvate levels, you heighten inflammatory disease," he adds. Petty wonders whether one day enzyme levels could be tested early in pregnancy to predict the likelihood of developing pre-eclampsia or other complications.

It is possible, says Petty, that the general mechanisms described in the current study may apply to more than one complication of pregnancy. This possibilityand that of designing drugs to suppress pyruvate kinase activityis the focus of future research. "I have a long list of things I'd like to see developed for the clinic in the next five years," adds Petty.


'/>"/>

Contact: Betsy Nisbet
bsnisbet@umich.edu
734-647-5586
University of Michigan Health System
Source:Eurekalert

Related biology news :

1. Medical researchers discovery may explain how certain cancers develop
2. Long-term use of certain contraception injections associated with increased fracture risk
3. Mango effective in preventing, stopping certain colon, breast cancer cells
4. Ongoing human evolution could explain recent rise in certain disorders
5. Consumption of certain fish during pregnancy associated with poorer cognitive performance
6. MSU discoveries upend traditional thinking about how plants make certain compounds
7. Shellfish face an uncertain future in a high CO2 world
8. New evidence explains poor infant immune response to certain vaccines, says MU researcher
9. Study unravels why certain fishes went extinct 65 million years ago
10. Dealing with taxonomic uncertainty for threatened and endangered species
11. UCSB scientists show how certain vegetables combat cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/1/2016)... NEW YORK , Feb. 1, 2016  Today, ... Heart Association (AHA) announced plans to develop a first ... cognitive computing power of IBM Watson. In the first ... disease, AHA, IBM (NYSE: IBM ), and Welltok ... metrics and health assessments with cognitive analytics, delivered on ...
(Date:1/27/2016)... CHESTER, Ohio , Jan. 27, 2016  Rite ... supplier based in West Chester, Ohio ... their award winning service staff, based in ... technical capacity and ability to provide modifications, installations and ... John Dovalina , CEO of PLUS, commented, "PLUS has ...
(Date:1/22/2016)... , January 22, 2016 /PRNewswire/ ... announced the addition of the  "Global ... their offering. --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ... the  "Global Behavioral Biometric Market 2016-2020" ... Research and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) ...
Breaking Biology News(10 mins):
(Date:2/4/2016)... ... February 04, 2016 , ... ... leading supplier of Semantic Graph Database technology has been recognized As “ Best ... by Corporate America Magazine. , “At Corporate America, it’s our priority to showcase ...
(Date:2/3/2016)... , Feb. 3, 2016   ViaCyte, ... with the first pluripotent stem cell-derived islet replacement ... in clinical-stage development, today announced that ViaCyte and ... Companies of Johnson & Johnson, have agreed to ... into ViaCyte.  The agreement provides ViaCyte with an ...
(Date:2/3/2016)... Denmark , Feb. 3, 2016 Ascendis ... biotechnology company that applies its innovative TransCon technology to ... present at an upcoming investor conference.Event:2016 Leerink Partners Global ... NY Date:  , Wednesday, February 10, 2016 Time:  ... www.ascendispharma.com . --> An audio webcast ...
(Date:2/3/2016)... ... February 03, 2016 , ... Aerocom, a world-leading supplier ... the North American healthcare market. , Aerocom Healthcare, LLC will be based in ... will provide new pneumatic tube systems or expand existing systems within the U.S. ...
Breaking Biology Technology: